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Background: Determining the driving factors and molecular flow-through that define the switch from favorable to
aggressive high-risk disease is critical to the betterment of neuroblastoma cure.
Methods: In this study, we examined the cytogenetic and tumorigenic physiognomies of distinct population of
metastatic site- derived aggressive cells (MSDACs) from high-risk tumors, and showed the influence of acquired
genetic rearrangements on poor patient outcomes.
Results: Karyotyping in SH-SY5Y and MSDACs revealed trisomy of 1q, with additional non-random chromosomal
rearrangements on 1q32, 8p23, 9q34, 15q24, 22q13 (additions), and 7q32 (deletion). Array CGH analysis of individual
clones of MSDACs revealed genetic alterations in chromosomes 1, 7, 8, and 22, corresponding to a gain in the copy
numbers of LOC100288142, CD1C, CFHR3, FOXP2, MDFIC, RALYL, CSMD3, SAMD12-AS1, and MAL2, and a loss in ADAM5,
LOC400927, APOBEC3B, RPL3, MGAT3, SLC25A17, EP300, L3MBTL2, SERHL, POLDIP3, A4GALT, and TTLL1. QPCR analysis
and immunoblotting showed a definite association between DNA-copy number changes and matching
transcriptional/translational expression in clones of MSDACs. Further, MSDACs exert a stem-like phenotype. Under
serum-free conditions, MSDACs demonstrated profound tumorosphere formation ex vivo. Moreover, MSDACs
exhibited high tumorigenic capacity in vivo and prompted aggressive metastatic disease. Tissue microarray analysis
coupled with automated IHC revealed significant association of RALYL to the tumor grade in a cohort of 25
neuroblastoma patients. Clinical outcome association analysis showed a strong correlation between the expression
of CFHR3, CSMD3, MDFIC, FOXP2, RALYL, POLDIP3, SLC25A17, SERHL, MGAT3, TTLL1, or LOC400927 and overall and
relapse-free survival in patients with neuroblastoma.
Conclusion: Together, these data highlight the ongoing acquired genetic rearrangements in undifferentiated
tumor-forming neural crest cells, and suggest that these alterations could switch favorable neuroblastoma to
high-risk aggressive disease, promoting poor clinical outcomes.
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Neuroblastoma (NB) is the most common cancer of in-
fancy [1]. It originates from the sympathoadrenal lineage
of the neural crest and accounts for 9.1 % of cancer-
related deaths in children [2]. The clinical hallmark of
NB heterogeneity is its marked variability in prognosis,
ranging from spontaneous regression to an aggressive
clinical course followed by death [3]. Despite intensive
multimodal therapy, which may include chemotherapy,
surgery, radiotherapy, myeloablative chemotherapy with
autologous stem cell transplant, and/or differentiation
therapy, high-risk aggressive NB remains one of the
most difficult cancers to cure [4, 5]. Given its heterogen-
eity, resistance, and poor hematological reserve, the rate
of 5 year overall survival (OS) is low (<10 %) in patients
with high-risk disease, compared with 65 % 5 year OS in
patients with low- or intermediate-risk disease. The rate
of long-term survival is even more dismal in 10 years
after diagnosis, with only 2 % OS for patients with stage
4 compared with 38–71 % for patients with low-risk dis-
ease [6, 7]. High-risk aggressive disease is typically char-
acterized by a wide range of genomic alterations,
including point mutations, copy number changes, and
genetic rearrangement [8, 9]. In this study, we attempted
to characterize the genetic alterations in highly malig-
nant aggressive cells. These alterations could define the
switch from favorable NB to high-risk aggressive disease.
NB is characterized by non-random chromosomal ab-
normalities with diagnostic and prognostic significance,
including large-scale chromosomal imbalances [10–14].
Traditional cytogenetic analysis of SH-SY5Y cells suc-
cessfully described some abnormalities [15–17]. Array
comparative genomic hybridization provided additional
molecular cytogenetic insights into the SH-SY5Y cell line
karyotype [18, 19]. Comprehensive molecular cytogen-
etic approaches that reveal the presence of previously
undetected allelic imbalances and copy number varia-
tions are usually well-suited to studying segmental rear-
rangements, such as the deletion of 1p or 11q, gain of
17q, and MYCN proto-oncogene amplification [20, 21].
MYCN status, tumor ploidy, and 11q23 allele status have
been included in the International Neuroblastoma Risk
Group (INRG) classification system [22]. Recent studies
showed that the karyotype changes observed during
propagation encompass genomic regions that are fre-
quently altered in human cancer, providing the cancer-
ous cells with a survival or growth advantage [23]. The
frequent relapses that are seen in aggressive NB, with
decreasing time intervals between relapses, highlight the
genetic rearrangements that could drive ongoing acquisi-
tion of chemo/radio-resistance and pro-oncogenic adap-
tations [24, 25]. Identifying the crucial genetic alterations
or rearrangements that switch favorable NB to aggressive
high-risk NB could lead to the development of an efficientand improved targeted therapeutic strategy and better pa-
tient outcomes.
This study used spontaneous and reproduced mouse
models of aggressive human NB to document acquired
genetic alterations in the NB cells, and further identified
the gene manipulations orchestrated as a cause effect.
We established clones of distinct populations with ag-
gressive physiognomy (MSDACs), using tumors derived
from multiple metastatic sites of various animals. These
clones were examined for genetic rearrangements, can-
cer stem cell (CSC) status, and ability to prompt aggres-
sive disease with systemic metastasis. Clinical outcome
association studies in cohorts of neuroblastoma patients
showed a strong association of these acquired genetic re-
arrangements with poor overall and relapse-free survival.
For the first time, this study demonstrated the ongoing
acquisition of genetic rearrangements and the subse-
quent switch from favorable NB to high-risk disease,
identifying an association between genetic rearrange-




The SH-SY5Y human neuroblastoma cell line was ob-
tained from ATCC (Manassas, VA) and was cultured
and maintained as described earlier [26]. For passaging
and for all experiments, the cells were detached using
0.25 % trypsin /1 % EDTA, resuspended in complete
medium, counted (Countess, Invitrogen), and incubated
in a 95 % air/5 % CO2 humidified incubator.
Development of neuroblastoma xenografts and mouse
model of high-risk metastatic disease
All animal experiments conformed to American Physio-
logical Society standards for animal care and were car-
ried out in accordance with guidelines laid down by the
National Research Council. All protocols were approved
by the University of Oklahoma Health Sciences Center -
Institutional Animal Care and Use Committee. However,
Human data used were obtained from public database
(http://r2.amc.nl) to demonstrate the significance of
altered genes in high-risk disease and their relevance to
clinical outcomes. Neuroblastoma xenograft and/or ag-
gressive metastatic disease development was performed
as described earlier [27]. Tumor growth, regression, and
dissemination to distant sites were investigated by
tumor volume measurements and non-invasive fluores-
cent imaging as described earlier [27]. Animals were
euthanized by CO2 asphyxiation. The tumors from
metastatic sites and non-metastatic xenografts were
harvested and prepared as single-cell suspensions as
described earlier [27]. To reproduce high-risk aggressive
disease, animals were injected with isolated and well-
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vidual metastatic sites, and observed for development of
metastatic tumors. Parallel experiments were performed
with parental SH-SY5Y cells as describe earlier [27].
Tumorosphere formation capacity
We plated a total of 103 parental SH-SY5Y cells and
MSDACs maintained under ex vivo controlled conditions
on 100 mm culture plates in serum-free stem cell medium
(DMEM:F12 with 1 % N2 Supplement, 2 % B27 Supple-
ment, 20 ng/ml hPDGF, 100 ng/ml EGF, and 1 %
antibiotic-antimycotic). Cells were maintained at 37 °C,
5 % CO2 for 72 h. We assessed formation of well-
organized tumorospheres using phase contrast light
microscopy. In parallel, we examined 1000 cells plated
in 96-well culture plates with high-content real-time
fluorescent time-lapsed video imaging as described
earlier [28].
Routine cytogenetics (G-banding analysis) and array CGH
All cell preparations for cytogenetic analysis, karyotyping,
and array CGH were performed in the Cytogenetic Mo-
lecular division of the University of Oklahoma Health
Sciences Center Clinical Genetics Core. We harvested
parental SH-SY5Y cells and MSDACs according to our la-
boratory standard protocols. Chromosomes were treated
and stained by trypsin-Giemsa banding (GTG-banding). A
total of 50 cells were analyzed and karyotyped (in a
blinded fashion) from each clone of the cell line. For array
CGH, genomic DNA was extracted from the parental SH-
SY5Y, and aggressive MSDACs by the phenol-chloroform
method with slight modifications, as described previously
[29]. A total of 1.5 μg of Cyanine 5-dUTP-labeled test
DNA and an equal amount of Cyanine 3- dUTP-labeled
reference DNA were mixed using a NimbleGen Dual-
Color DNA Labeling Kit, and then hybridized to a high
capacity NimbleGen CGH array (3 × 1.4 M features,
Roche NimbleGen Inc., Madison, WI) according to Nim-
bleGen’s CGH protocols. The arrays were scanned at
532 nm and 635 nm using a NimbleGen MS200 Micro-
array Scanner. Nexus Copy Number™ software version 7.0
(BioDiscovery Inc., Hawthorne, CA) was used to visualize,
detect, and analyze array CGH differences.
QPCR
We used real-time QPCR to analyze the transcriptional al-
terations of ADAM5, A4GALT, APOBEC3B, CD1C,
EP300, FOXP2, SLC25A17, L3MBTL2, MAL2, NBPF20,
POLDIP3, RALYL, and SERHL (corresponding genes for
the observed copy number variation) in SH-SY5Y and in
clones of MSDACs grown ex vivo as described earlier [26,
30]. We used β-actin as a positive control. A negative con-
trol without template RNA was also included. Each ex-
periment was carried out in triplicate. The ΔΔCt valueswere calculated by normalizing the gene expression levels
to β-actin. The relative expression level was expressed as a
fold change over parental SH-SY5Y cells. Group-wise
comparisons were performed with two-way ANOVA with
Tukey’s post-hoc correction (Prism Version 4.03, Graph-
Pad Software Inc., La Jolla, CA).
Immunoblotting
Total protein extraction and immunoblotting were per-
formed as described in our earlier studies [20, 24]. For
this study, the protein transferred membranes were in-
cubated with either Rabbit polyclonal RALYL or Goat
monoclonal FoxP2 (Abgent, San Diego, CA) and were
developed with the appropriate anti-goat/anti-rabbit
(BioRad Laboratories, Hercules, CA) secondary antibody.
Tissue microarray and, quantitative immunohistochemistry
All tissue microarrays (TMA) IHC staining were per-
formed in the Stephenson Cancer Center Cancer Tissue
Pathology Core. To better characterize the correlation
between acquired alterations of RALYL to the neuro-
blastoma progression in clinical subjects, we used a
commercially available human neuroblastoma tissue
array (Cat. No. MC-602, US Biomax, Inc., Rockville,
MD). The 5 μm thick human TMA is equipped with du-
plicate 1.5 mm cores of neuroblastoma tissues from vari-
ous sites including the retroperitoneum, mediastinum,
abdominal and pelvic cavities, and the adrenal glands of
25 patients. Further, the TMA is armed with clinical var-
iables including sex, age, site/organ, diagnosis, and
tumor grading. Pathology diagnosis classification in-
cludes: (i) Grade 1 or well-differentiated - Cells appear
normal and are not growing rapidly; (ii) Grade 2 or
moderately-differentiated - Cells appear slightly differ-
ent than normal; (iii) Grade 3 or poorly differentiated
- Cells appear abnormal and tend to grow and spread
more aggressively. H & E stained TMA was reviewed for
pathology. For this study, TMA-IHC staining was per-
formed with Rabbit polyclonal RALYL (Abgent). The
slides were micro-digitally scanned using an Aperio
Scanscope (Aperio Technologies, Inc.,) slide scanner and
analyzed using integrated Spectrum software. RALYL
nuclear positivity for the cores was then correlated with
tumor grades. Group-wise comparisons were performed
with GraphPad Prism.
Functional characterization of genetic alterations and
association to clinical outcomes
We used Ingenuity Pathway Analysis software (Ingenuity
Systems, Inc.) to examine the intermolecular interactions
and the role that the genes with altered copy numbers
and expression played in cancer progression. In this way,
we were able to characterize the genetic rearrangements
observed to accompany the functional biological
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used the R2: microarray analysis and visualization plat-
form (http://r2.amc.nl) created by Dr. Jan Koster at the
Academic Medical Center (AMC), Amsterdam, to exam-
ine the association of the observed genetic alterations
with overall and relapse-free survival. This web-based
application correlates a select gene expression profile
with clinical outcomes for samples from various cohorts
of patients.
Results
Human neuroblastoma (SH-SY5Y) cells with mixed
neuroblast-like and epithelial-like cells develop spontan-
eous high-risk aggressive disease in vivo
The subcutaneous administration of human SH-SY5Y
cells resulted in the development of ~200 mm3 xenografts
in ~70 % of the animals within 30 days, as described previ-
ously [26, 31], while the other 30 % of the mice were pre-
sented with multiple clinically-mimicking aggressive
metastatic tumors in the mediastinum and retroperiton-
eal, pelvic, abdominal, and chest cavities as shown previ-
ously (27).
Aggressive CSC-like MSDACs prompt tumorigenicity and
reproduce high-risk disease
To better characterize the established high-risk aggres-
sive disease model and to underscore the enrichment of
select clones from the parental line or ongoing acquisi-
tion of genetic rearrangements, MSDAC clones were
discretely characterized by karyotyping, whole genome
array CGH analysis, and tumorosphere-forming capacity.
MSDACs are relatively small and spherical with thin
neurites. More importantly, every investigated clone of
MSDACs exhibited intrinsic CSC characteristics per the
ability to readily grow ex vivo in serum-free medium and
form large organized tumorospheres (28). This process is
presumed to simulate the events of tissue regeneration
and maintenance from cells that survive suspension con-
ditions. In this process, an initial phase of symmetric ex-
pansion of the seeding stem cells precedes a phase of
asymmetric division, which gives rise to the differentiated
progeny that comprise the sphere bulk. Real-time high-
content observation of MSDACs under controlled condi-
tions showed an aggressive aggregation and tumorosphere
formation within 18 h (Fig. 1; Additional file 1: video 1 and
Additional file 2: video 2). Though parental SH-SY5Y cells
and cells derived from non-metastatic xenografts (Fig. 1)
survived in serum-free medium, they exhibited mono-
layer cell spreading without tumorosphere formation.
In vivo, subcutaneous administration of MSDACs pro-
duced relatively large (>500 mm3) xenografts as reported
earlier [27]. The mice that received MSDACs presented
with multiple metastatic tumors in the retroperitoneal, pel-
vic, abdominal, and chest cavities, demonstrating thereproducibility of the high-risk aggressive disease. Con-
versely, the mice that received parental cells did not exhibit
any distant metastasis, and hence served as the non-
metastatic xenograft controls.
G-banding certified that MSDACs from metastatic mouse
tumors are derived from human SH-SY5Y cells
Cancer cells are typically characterized by intricate kar-
yotypes, including both structural and numerical changes.
To determine and illustrate that the aggressive tumors de-
veloping in multiple metastatic sites were derived from
the parental human SH-SY5Y cells, we karyotyped
MSDACs, with and without characterized CD133+, and
compared these with the parental cells. All karyotyping
was performed in double blinded fashion. We investigated
at least 20 cells per clone. SH-SY5Y cells exhibited the
47,XX, add(1)(q32), +del(7)?(q32), add(8)(p23), add(9)(q34),
add(15)(q24), add(22)(q13) [20] karyotype, and served as
the positive controls (Fig. 2ai). All investigated clones of
MSDACs exhibited an exact match of the parental SH-
SY5Y cells. We observed a unique marker composed of a
chromosome 1 with a complex insertion of an add-
itional copy of a 1q segment into the long arm, result-
ing in trisomy of 1q. Karyotyping also revealed six
novel non-random chromosomal rearrangements on
1q32, 8p23, 9q34, 15q24, 22q13 (additions), and 7q32
(deletion; Fig. 2aii). Consistently, array CGH analysis
corroborated the karyotyping in the clones of parental
cells and MSDACs (Fig. 2b) and demonstrated that the
developed aggressive metastatic tumors in mice are in-
deed derived and disseminated from the parental SH-
SY5Y cells.
Acquired genetic rearrangements in neuroblastoma cells
drive aggressive disease
To determine any acquired genetic rearrangements and
to underscore their impact on disease progression, we
utilized high-throughput whole genome array CGH ana-
lysis (Fig. 3a) coupled with quantitative transcriptional
expression (QPCR). High resolution array CGH analysis
showed unique yet extensive copy-number variations
(CNVs), including insertions, deletions, and more com-
plex changes that involve gain (duplication) or loss
(deletion) at the same locus in MSDAC clones (Fig. 3a,
Fig. 4). However, in order to characterize the association
of acquired genetic rearrangements with disease pro-
gression, we considered only the common genetic varia-
tions across the investigated clones of MSDACs. Forty-
five common CNVs were observed with gain in 30
(Chr.1,7; Chr.2, 3; Chr.4, 1; Chr.6, 1; Chr.7, 6; Chr.8, 8;
Chr.11,2; Chr.17,2) regions and loss in 15 (Chr.4,1;
Chr.8,1; Chr.14,1; Chr.22,12) regions (Fig. 3b, Fig. 4).
Interestingly, these CNVs correspond to the gain in the
coding regions of CD1C, CFHR3, FOXP2, MDFIC,
Fig. 1 Tumorosphere formation capacity of MSDAC. Representative time-lapse photomicrographs of high-content imaging of parental SH-SY5Y
and aggressive MSDACs. Cells were stained with DiI and imaged in real-time every 20 min for 18 h with Operetta. Parental cells (upper panel)
showed monolayer spreading, MSDACs (lower panel) showed aggregation and tumorosphere formation
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OR52N5, LOC400927, APOBEC3B, RPL3, MGAT3,
SLC25A17, EP300, L3MBTL2, SERHL, POLDIP3, A4GALT,
and TTLL1 genes. (Fig. 3b, Fig. 4). Unlike the healthy
genome, in which changes in gene expression are care-
fully controlled through transcription factors, the can-
cer genome adapts through the duplication of CD1C,
CFHR3, FOXP2, MDFIC, RALYL, CSMD3, SAMD12-
AS1, MAL2, and OR52N5, and loss in the coding re-
gions of ADAM5, LOC400927, APOBEC3B, RPL3,
MGAT3, SLC25A17, EP300, L3MBTL2, SERHL, POL-
DIP3, A4GALT, and TTLL1 genes. QPCR analysis re-
vealed a CNV gain with a corresponding increase in
transcriptional expression of CD1C, FOXP2, RALYL,
and MAL2 in MSDACs, but not in SH-SY5Y cells
(Fig. 5a). Likewise, we observed a transcriptional repres-
sion of ADAM5, A4GALT, ABPOBEC3B, EP300,
L3MBTL2, SERHL, SLC25A17, and POLDIP3, consistent
with the CNV loss in MSDACs (Fig. 5a). Moreover, im-
munoblotting analysis revealed a profound increase in
RALYL and FOXP2 translation in aggressive MSDAC
clones as opposed to the parental SH-SY5Y cells
(Fig. 5b). Like-wise we observed a robust increase inRALYL and FOXP2 expression in metastatic tumors
compared to the non-metastatic primary xenograft
(Fig. 5b). Quantity one densitometry analysis revealed
consistent increase in RALYL and FOXP2 expression
both in ex vivo and in vivo settings (Fig. 5b side panel).
Together, the definite genetic changes (CNV loss/gain)
in the coding regions of specific genes and their subse-
quent transcriptional/translational modulations across
MSDACs highlight the acquired genetic rearrangements
in neuroblastoma progression.
Acquired alterations associates with poor prognosis
To further substantiate our findings in clinical settings, we
examined whether gain/loss in the expression of such can-
didates correlates with high-risk neuroblastoma utilizing a
commercially available human neuroblastoma TMA. The
tissues are derived from sites including the retroperitoneal,
abdominal, and pelvic cavities, the mediastinum, and the
adrenal glands. RALYL-IHC analysis revealed a significant
distinction in RALYL staining between patient samples
(Fig. 6a). RALYL IHC revealed nuclear positivity with vari-
able levels the human neuroblastoma tissue cores analyzed.
Positive RALYL staining appeared in brown and was
Fig. 2 Karyotyping in parental SH-SY5Y and MSDACs. Representative microphotographs showing karyotyping patterns in parental SH-SY5Y and
MSDACs by (a) G-banding analysis and (b) array CGH analysis. G-banding identical 47,XX, add(1)(q32), +del(7)?(q32), add(8)(p23), add(9)(q34),
add(15)(q24), add(22)(q13) [20] karyotyping in SH-SY5Y and MSDACs
Khan et al. BMC Cancer  (2015) 15:514 Page 6 of 13selectively localized in the nucleus (see 40× panel, Fig. 6a).
Correlating the RALYL positivity to the tumor grade clearly
identified the directly proportional tumor-grade→RALYL
expression association (Fig. 6b). RALYL positivity was rela-
tively low in Grade 1, while its expression increased per in-
creased tumor invasive potential, with maximal gain in
highly invasive tumors (Fig. 6b).
Acquired genetic alterations are associated with tumor
progression and poor clinical outcomes
To underscore the importance of the observed genetic
rearrangements in aggressive disease, we first clarified
their biological functions, network and communal mo-
lecular orchestrations, and their documented role in any
tumor progression systems. IPA “pathway interaction
analysis” revealed a complex yet well-organized signal
transduction network of MAL2, A4GALT, POLDIP3,RPL3, EP300, CD1C, CFHR3, APOBEC3B, RALYL,
NBPF20, FOXP2, MDFIC, TTL1, and MGAT3
(Additional file 3: Figure S1). Evidently, genes with gen-
etic rearrangements in coding regions play concomitant
roles in multiple tumor systems, such as chronic mye-
loid leukemia, melanoma, small cell carcinoma, lung car-
cinoma, mammary tumor, prostate cancer, pancreatic
cancer, colon adenocarcinoma, squamous cell carcin-
oma, and non-small cell lung adenocarcinoma. More-
over, “IPA-Core-Analysis” revealed that this small subset
of tightly inter-regulated molecular targets showed influ-
ential participation in many canonical signaling path-
ways and demonstrated defined roles in multifarious
biological functions. IPA-data mining considering only
relationships where confidence = experimentally ob-
served, these molecules exhibited their role in at least 67
different canonical pathways exerting >150 biological
Fig. 3 Genome wide copy number variations in parental SH-SY5Y and MSDACs. a Array CGH analysis showing digitized copy number variations
(CNVs) across the genome plotted for SH-SY5Y cells and MSDACs. b Table showing common copy number gain and/or loss across the clones of
MSDACs. Chromosome numbers, regions, and magnitude of CNV variation and corresponding genes are shown
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and dissemination, we observed a significant association
of these molecules in key pathways of cancer progression
viz., ATM Signaling, cAMP-mediated signaling, Cell
Cycle:Checkpoint Regulation, CREB Signaling in Neurons,
Dendritic Cell Maturation, EIF2 Signaling, ERK/MAPK
Signaling, ERK5 Signaling, Estrogen Receptor Signaling,
FGF Signaling, FLT3 Signaling in Progenitor Cells, G-
Protein Coupled Receptor Signaling, Granzyme A Signal-
ing, HIF1a Signaling, ILK Signaling, Neurotrophin/TRK
Signaling, NFkB Signaling, p38 MAPK Signaling, p53 Sig-
naling, Phospholipase C Signaling, PPAR Signaling,
PPARa/RXRa Activation, Protein Kinase A Signaling,
RAR Activation, Pyrimidine Deoxyribonucleotides, TGF-b
Signaling, VDR/RXR Activation, Wnt/Ca + pathway, Wnt/
b-catenin Signaling etc., (Additional file 4: Figure S2A). In
addition to their role in molecular signaling events, these
molecules also exercise their defined (P < 0.05) roles incancer progression related bio-functions including Cancer
Cell Morphology, Progression of tumor, Cell Cycle-
replicative senescence, Cellular Assembly DNA Replica-
tion, Cell Cycle arrest, Cell Death and Survival, Cellular
Function and Maintenance, Post-Translational Modifi-
cation, Cell-To-Cell Signaling, Cellular Assembly/
Organization, Cellular Growth and Proliferation, Cellu-
lar Movement, Cellular Response to Therapeutics etc.,
(Additional file 4: Figure S2B). To that note, all-
encompassing overview of these molecules including
information on their symbol, name, subcellular loca-
tion, protein functions, binding, regulating, regulated
by, targeted by miRNA, role in cell, molecular function,
biological process, cellular component, disease, role in
tumor progression and metastasis etc., are provided in
Additional file 5: Table S1.
To demonstrate the relevance of these genetic rear-
rangements to high-risk neuroblastoma and poor clinical
Fig. 4 Copy number variations in parental SH-SY5Y and MSDACs. Representative copy number variation charts showing gain in Chr.1, 158.35–
160.00 MB; Chr.7, 114.084–114.115 MB; Chr.8, 39.25–39.40 MB, and in Chr.8, 84.50–85.75 MB, corresponding to the coding regions of CD1C, FOXP2,
ADAM5, and RALYL, respectively, in MSDACs compared with SH-SY5Y cells
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gene expression with overall (OS) and relapse-free sur-
vival in patients with neuroblastoma. We utilized a web-
based microarray analysis and visualization platform
(http://r2.amc.nl) that correlates a select gene expression
profile with clinical outcomes for samples from multiple
cohorts of patients with neuroblastoma. Kaplan-Meier
plots showed a significant association between increased
expression of CFHR3, MDFIC, CSMD3, FOXP2, or
RALYL (genes with gains in coding regions) and poor
OS in patients with neuroblastoma (Additional file 6:
Figure S3A). This inverse association of CFHR3-,
MDFIC-, CSMD3-, FOXP2-, or RALYL-gain also reflects
poor relapse-free survival in these patients (Additional
file 6: Figure S3A). Interestingly, SLC25A17, POLDIP3,
SERHL, LOC400927, MGAT3, or TTLL1 (genes with
CNV-loss in coding regions) demonstrated a definite as-
sociation with their loss and poor OS (Additional file 6:
Figure S3B). The loss in any of these genes individuallyresults in poor relapse-free survival in children with
neuroblastoma (Additional file 6: Figure S3B). Clinical
outcome association analysis also revealed a strong cor-
relation between the expressional variations of both
groups of genes listed above and stage progression, fa-
vorable→ unfavorable disease and alive→ died-of-dis-
ease (data not shown). It is pertinent to mention that
gains in CD1C, NBPF20, and MAL2, and losses in
ADAM5, RPL3, L3MBTL2, A4GALT, EP300, and APO-
BEC3B were not associated with poor clinical outcomes
(Additional file 7: Figure S4). Together, these data dem-
onstrate the direct, definite influence of genetic rear-
rangements in aggressive disease on poor clinical
outcomes in children with neuroblastoma.
Discussion
The most devastating aspect of high-risk neuroblastoma
is the hematogenous metastasis that produces frequent
relapse, evades intense multi-modal therapy, and
(A)
(B)
Fig. 5 Transcriptional and translational validation array CGH outcomes. a Histograms of QPCR analysis showing transcriptional amplification of
CD1C, FOXP2, RALYL, NBPF20, and MAL2, and suppression of APOBEC3B, SLC25A17, EP300, L3MBTL2, SERHL, A4GALT, POLDIP3, and ADAM5 in clones
of MSDACs compared with SH-SY5Y cells. b Representative immunoblots showing the expression level of RALYL and FOXP2 (both showed gain
in Array CGH analysis) in two different clones of metastatic site derived aggressive cells (MSDAC) in comparison with the parental SH-SY5Y cells
and in the metastatic tumors derived from three different animals bearing high-risk aggressive neuroblastoma (NB-MT-AD) in comparison with
the non-metastatic primary xenograft (NB-NM-PX). Side Panel: Histograms of Quantity one densitometry analysis showing robust increase in
RALYL and FOXP2 expression in MSDACs as well as in metastatic tumors in vivo
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cancer progression is attributed to the ongoing accumula-
tion of genetic alterations in tumor cells [33], it is critical
to describe the genetic rearrangements that prompt and
orchestrate the switch from favorable to aggressive high-
risk neuroblastoma. For the first time, this study identified
the acquired genetic rearrangements in highly malignant
populations of neuroblastoma cells that reproduced
clinically-mimicking aggressive disease. We found that the
acquired genetic rearrangements in these cells correspond
to the coding regions of a unique set of genes, and further
translate to the altered transcriptional and translational
regulation of these genes. Strikingly, we found a strong as-
sociation of these accumulated genetic rearrangements
with poor overall and relapse-free survival.High-resolution whole genome array CGH analysis
identified a distinctive set of genetic rearrangements
(gain/loss) that were common across the highly malig-
nant MSDACs. Over the last two decades, identification
of numerous oncogenes and tumor suppressors has
aided the study of genetic alterations in cancer cells and
helped us understand tumor progression and metastasis
[34, 35]. Outcomes from studies using large cancer data-
bases illustrated that accumulated genetic alterations
may drive phenotypical and biological heterogeneity in
tumor cells [3, 36]. Moreover, studies have shown that
highly malignant cells often acquire alterations in more
genes than do non-metastatic cells; metastatic and non-
metastatic cells also express genes differently [37, 38]. In
this study, we observed acquired genetic alterations in the
(A) (B)
(40x)
Fig. 6 Tumor grade associated expression of RALYL in human neuroblastoma. a Thumbnail and constructed images (20×) of human
neuroblastoma tissue microarray coupled with automated IHC showing RALYL expression levels in human neuroblastoma samples (n = 25). b
Aperio image analysis of the TMA and RALYL positivity quantification and subsequent correlation of RALYL expression with neuroblastoma tumor
grading
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CSMD3, SAMD12-AS1, MAL2, OR52N5, ADAM5,
LOC400927, APOBEC3B, RPL3, MGAT3, SLC25A17,
EP300, L3MBTL2, SERHL, POLDIP3, A4GALT, and
TTLL1. Despite the extensive correlation studies that have
been previously conducted, to our knowledge this is the
first study that identifies the accumulated genetic rear-
rangements in this setting.
Cytogenetic analysis now extends beyond the simple de-
scription of the chromosomal status of a genome, and al-
lows the study of in-depth essential biological questions,
including the nature of inherited syndromes, genomic
changes involved in tumorigenesis, and three-dimensionalorganization of the human genome [39]. The results pre-
sented here show the robust tumorosphere-forming cap-
acity of MSDACs ex vivo. Further, the results provide
evidence of aggressive tumor-forming potential with mul-
tiple metastases of MSDACs in vivo. These outcomes il-
lustrate the clonal enrichment of a select genetically
modified, highly malignant sub-population disseminating
to distant sites and promoting aggressive disease. To
understand the acquired genetic rearrangements in these
cells, array CGH coupled with QPCR and immunoblotting
are ideal tools. Since cancer stem cells play an instrumen-
tal role in cancer relapse and tumor progression [40, 41],
exhibition of CSC status in these highly malignant cells
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ments and the subsequent drive from favorable to aggres-
sive NB.
Substantiating our findings of acquired genetic rear-
rangements in the development of aggressive disease,
both G-banding and array CGH results confirmed the
parental SH-SY5Y cell derivation. Human SH-SY5Y cells
are a unique neuroblastoma line composed of N-type
and S-type cells [32]. Since the discovery of tumor cell
heterogeneity, indicating that a primary tumor often
contains sub-populations of metastatic and non-
metastatic cancer cells [42], a plethora of evidence cor-
roborating cell heterogeneity to metastatic potential has
been found in many tumor systems [43]. In this study,
we established clones of MSDACs with high-metastatic
potential from a manifold of tumors from metastatic
sites of various mice. These cells exhibited CSC physi-
ognomy with ready growth in serum-free conditions and
well-organized tumorosphere formation. In addition, the
cells reproduced clinically relevant aggressive disease
with multiple metastases. More importantly, the results
showed differential CNV loss or gain and corresponding
gene/protein expression in metastatic MSDACs and
non-metastatic cells. Since the differentially expressed
genes will induce or suppress tumor progression [33], it
is crucial to analyze both gain and loss. For the first
time, this study identified a strong clinical outcome as-
sociation with both CNV gain/increased gene expression
and CNV loss/suppressed gene expression. However, the
acquired gain in CFHR3, MDFIC, CSMD3, FOXP2, or
RALYL and loss in SLC25A17, POLDIP3, SERHL,
LOC400927, MGAT3, or TTLL1 drive poor patient
outcomes.
To better understand how cancer cells acquire aggres-
sive metastatic potentials, we must clarify the causative
genetic alterations unique to cancer cells with metastatic
ability [37, 38]. Researchers have hypothesized that a
number of oncogenes or tumor suppressors that are
genetically altered in cancer cells undergo ongoing accu-
mulation during tumor progression, and are causative
events for multistage carcinogenesis. However, no single
oncogene, tumor suppressor, or gene group has been
shown to be responsible for the acquisition of invasive-
ness and metastatic potential in cancer cells. This line of
study requires a bidirectional molecular approach, in-
cluding identification of the genes whose genetic alter-
ations accumulate during cancer progression and
identification of genes whose expression is responsible
for the acquisition of metastatic potential in cancer cells.
We believe the results presented here comprehensively
address both questions in the setting of high-risk aggres-
sive neuroblastoma, where (a) genetic rearrangements
with array CGH, QPCR and immunoblotting identified
the genes whose genetic alterations accumulate duringneuroblastoma progression and (b) clinical outcomes
(overall survival) association studies as well as clinical
tumor grade-correlated RALYL expression identified
genes whose expression may be responsible for the ac-
quisition of aggressive disease.
Conclusions
In conclusion, the results of this study show an accumu-
lation of genetic rearrangements in neuroblastoma cells
that drive high-risk aggressive metastatic disease. Specif-
ically, there is CNV gain in the coding regions and con-
forming expressions of CD1C, CFHR3, FOXP2, MDFIC,
RALYL, CSMD3, SAMD12-AS1, MAL2, and OR52N5,
and CNV loss in coding regions and associated regula-
tion of ADAM5, LOC400927, APOBEC3B, RPL3,
MGAT3, SLC25A17, EP300, L3MBTL2, SERHL, POL-
DIP3, A4GALT, and TTLL1. Highly malignant MSDACs
that were derived from metastatic sites exhibited CSC
status and exerted robust tumorosphere formations
ex vivo. These MSDACs also initiated and reproduced
high-risk aggressive metastatic disease in vivo. Clinical
outcome association analysis recognized and identified a
strong association with the gain in CFHR3, FOXP2,
MDFIC, RALYL, or CSMD3 and loss in SLC25A17,
SERHL, POLDIP3 LOC400927, MGAT3, or TTLL1 and
poor overall and relapse-free survival. This study de-
scribed the novel genetic alterations that accumulate
during neuroblastoma progression, and defined the role
of acquired genetic rearrangements in the clinical out-
comes of children with high-risk aggressive metastatic
neuroblastoma.
Additional files
Additional file 1: Video-1. Representative reconstructed video from
time-lapsed photomicrographs of high-content imaging parental SH-
SY5Y cells. Cells were stained with DiI and imaged in real-time for every
20 min for 18 h with Operetta.
Additional file 2: Video-2. Representative reconstructed video from
time-lapsed photomicrographs of high-content imaging of aggressive
MSDACs. Cells were stained with DiI and imaged in real-time every
20 min for 18 h with Operetta. MSDACs showed aggregation and
tumorosphere formation.
Additional file 3: Figure S1. Inter-regulation and network of array CGH
identified molecules: Ingenuity pathway analysis showing the interplay of
the gene that were identified to have corresponding copy number gain
or loss with array CGH analysis, including MAL2, A4GALT, POLDIP3, RPL3,
EP300, CD1C, CFHR3, APOBEC3B, RALYL, NBPF20, FOXP2, MDFIC, TTL1,
and MGAT3.
Additional file 4: Figure S2. IPA core analysis classification of tumor
progression/dissemination related canonical pathways and bio function
of array CGH identified molecules: (A) Histograms of IPA-data mining
considering only relationships where confidence = experimentally
observed, showing significant association of array CGH identified
molecules in key canonical signaling pathways related of cancer
progression. (B) Histograms of IPA-data mining (only relationships
where confidence = experimentally observed) showing roles of array
CGH identified molecules in in cancer progression related bio-functions.
Khan et al. BMC Cancer  (2015) 15:514 Page 12 of 13Additional file 5: Table S1. Comprehensive encompassing overview of
array CGH identified molecules including the information on their
symbol, name, subcellular location, protein functions, binding, regulating,
regulated by, targeted by miRNA, role in cell, molecular Function,
biological Process, cellular component, disease and, role in tumor
progression and Metastasis.
Additional file 6: Figure S3. Correlation of ‘gain’ in CFHR3, FOXP2, MDFIC,
RALYL, or CSMD3 and ‘loss’ in SLC25A17, SERHL, POLDIP3 LOC400927, MGAT3,
or TTLL1 with clinical outcomes in samples from NB patients: Gene
expression-associated clinical outcomes were assessed using the web-based
R2: microarray analysis and visualization (http://r2.amc.nl) platform. (A)
Kaplan-Meier curves computed for a cohort of 88 neuroblastoma patients
showing decreased overall and relapse-free survival in patients with high
levels of CFHR3, FOXP2, MDFIC, RALYL, or CSMD3. (B) Kaplan-Meier curves
computed for a cohort of 88 neuroblastoma patients showing decreased
overall and relapse-free survival in patients with low levels of SLC25A17,
SERHL, POLDIP3 LOC400927, MGAT3, or TTLL1.
Additional file 7: Figure S4. Kaplan Meier plots showing clinical
outcomes in a cohort of 88 neuroblastoma patients in association with
the expression pattern of CD1C, NBPF20, MAL2 (observed copy number
gain in the current study) and ADAM5, A4GALT, RPL3, L3MBTL2, APOBEC3B
and EP300 (observed copy number loss in the current study).
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